featured
Reduction of Daily Maintenance Inhaled Corticosteroid Dose in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
Lancet 2023 Dec 07;[EPub Ahead of Print], DJ Jackson, LG Heaney, M Humbert, BD Kent, A Shavit, L Hiljemark, L Olinger, D Cohen, A Menzies-Gow, S KornFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.